What happened to Progenics Pharmaceuticals?
Progenics Pharmaceuticals was acquired by Lantheus Holdings on Oct 3, 2019 .
Is ZNTL a buy?
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) The 10 analysts offering 12-month price forecasts for Zentalis Pharmaceuticals Inc have a median target of 78.50, with a high estimate of 120.00 and a low estimate of 51.00. The median estimate represents a +156.87% increase from the last price of 30.56.
Who bought Progenics?
Under the deal, Lantheus’ holding company will purchase all of Progenics’ issued and outstanding common shares—in exchange for 0.2502 shares of Lantheus stock for each—which will represent about a 35% ownership stake in the combined venture going forward.
What type of company is Lantheus Medical Imaging?
We are an established leader in the development, manufacture and commercialization of pioneering diagnostic and therapeutic products and artificial intelligence (AI) solutions. Our broad portfolio features: Precision Diagnostics that Find and Follow diseases in non-oncologic conditions.
Why is Zentalis stock dropping?
Zentalis Pharmaceuticals drops 30% following ovarian cancer candidate data. Shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) dropped 30% on Friday after releasing initial phase 1b efficacy data on its candidate, ZN-c3, in combination with chemotherapy in heavily pretreated ovarian cancer patients.
What is Pgnx?
Progenics Pharmaceuticals (PGNX)
Is Lantheus a public company?
In June 2015, parent company Lantheus Holdings [LNTH] became a NASDAQ listed company.
What does Lantheus Medical Imaging do?
About us Lantheus provides innovative diagnostics, targeted therapeutics and artificial intelligence (AI) solutions that empower clinicians to Find, Fight and Follow® disease. For more than 60 years, Lantheus has delivered life-changing science to patients and providers, going further to improve outcomes and lives.
When did lantheus acquire Progenics?
In June 2015, parent company Lantheus Holdings [LNTH] became a NASDAQ listed company. In 2020, Lantheus acquired Progenics Pharmaceuticals. The Progenics acquisition added a pipeline of radiotherapeutics, targeted PET imaging agents and small molecule therapeutics in the oncology space.
When did lantheus go public?
Lantheus Holdings is registered under the ticker NASDAQ:LNTH . Their stock opened with $6.00 in its Jun 18, 2015 IPO.
Is lantheus a good company to work for?
Lantheus Medical Imaging is a great workplace and has a fantastic crew of individuals and comfortable workplace culture. Everyone is approachable and most things are organized with a few hiccups from time to time seen in any work space.
Is lantheus a public company?
What is Progenics Pharmaceuticals’stock price today?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol “PGNX.” What is Progenics Pharmaceuticals’ stock price today? One share of PGNX stock can currently be purchased for approximately $4.10.
What companies do Progenics Pharmaceuticals investors own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), IMAX (IMAX), Novavax (NVAX), Cara Therapeutics (CARA), OPKO Health (OPK), Citius Pharmaceuticals (CTXR) and Dynavax Technologies (DVAX).
What is Progenics Pharmaceuticals’mailing address?
Progenics Pharmaceuticals’ mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.